ARA-290 (CIBINETIDE) INJECTOR PEN 3ML

ARA-290 (Cibinetide): The Selective Innate Repair Receptor Agonist for Tissue Protection, Nerve Regeneration, and Anti-Inflammatory Healing
Now Available in the UAE

The ARA-290 or Cibinetide, is one of the first artificial peptides to be engineered from the three-dimensional structure of erythropoietin’s (EPO), tissue protective B-helix domain. It was made specifically to interact with the IRR, which is a heterodimer of the EPO receptor and the beta common receptor (CD131). The interaction between ARA-290 and the IRR results in anti-inflammatory, cytoprotective and regenerative properties that can result in systemic changes. Importantly, ARA-290 can achieve its systemic benefits without causing any increase in red blood cell production (erythropoiesis), thus avoiding some of the adverse effects associated with erythropoietic therapy, such as increased hematocrit levels, hyperviscosity syndrome or thrombosis.

As developed by Araim Pharmaceuticals, ARA-290 has been studied in several Phase II clinical trials examining Sarcoidosis Associated Small Fiber Neuropathy, Diabetic Neuropathy, and Metabolic Parameters in Type 2 Diabetes. As described above, its primary mechanism of action includes; suppression of pro-inflammatory M1 macrophages, promotion of reparative M2 macrophage activity, reduction of key pro-inflammatory cytokines (TNF-alpha, IL-1beta) and elevation of anti-inflammatory cytokine (IL-10), and direct anti-apoptotic protection against neuronal and other cellular damage. Therefore, ARA-290 represents a potentially valuable research tool for researchers studying tissue repair, neuropathic pain management, organ protection, and treatment of various chronic inflammatory diseases.

1. Significant Neuropathic Pain Relief and Nerve Fiber Regeneration
The ARA-290 is an effective agent for the treatment of the symptoms of small fiber neuropathy, which are due to damage to many nerve fibers. The drug works in two ways; it stimulates new growth of damaged nerve fibers and reduces inflammation within the nerves. In addition to this, the drug decreases spinal microglial activation (which leads to chronic inflammation), and increases both corneal and intraepidermal small nerve fiber density – two important indicators of disease modification as opposed to symptomatic improvement.

In a double-blind, placebo controlled Phase II study in patients with sarcoidosis, Brines et al. found significant increases in corneal small nerve fiber density and clinically relevant decreases in pain from neuropathic sources compared to those receiving the placebo. Studies have also shown improvements in functional performance (i.e. distance walked on the 6 minute walk test), and the degree of pain relief was correlated with long-term structural nerve repair.

2. Tissue Repair and Cellular Protection Without Erythropoietic Side Effects
Like other forms of recombinant EPO, ARA-290 causes specific activation of the IRR pathway which results in improved reparative function (tissue repair) at the organ level as well as protective effects against apoptosis and improves cellular tolerance to damage. As opposed to recombinant EPO, ARA-290 does not activate the EPO receptor homodimer that is responsible for bone marrow stimulation resulting in potential adverse effects including polycythemia, hypertension or thrombosis.

The selectivity of its action was defined by Brines et al. within the Journal of Biological Chemistry and their associated publications. Studies using pre-clinical models of injury, ischemia and inflammation have demonstrated rapid healing, decreased scarring and preservation of the structure of injured tissues without an effect on red blood cell count or hemoglobin level.

3. Potent Anti-Inflammatory Macrophage Reprogramming
Like other forms of recombinant EPO, ARA-290 causes specific activation of the IRR pathway which results in improved reparative function (tissue repair) at the organ level as well as protective effects against apoptosis and improves cellular tolerance to damage. As opposed to recombinant EPO, ARA-290 does not activate the EPO receptor homodimer that is responsible for bone marrow stimulation resulting in potential adverse effects including polycythemia, hypertension or thrombosis.

The selectivity of its action was defined by Brines et al. within the Journal of Biological Chemistry and their associated publications. Studies using pre-clinical models of injury, ischemia and inflammation have demonstrated rapid healing, decreased scarring and preservation of the structure of injured tissues without an effect on red blood cell count or hemoglobin level.

4. Improvements in Diabetic Neuropathy and Systemic Metabolic Parameters
The ARA-290 drug program targets both neuropathic consequences and metabolic derangements of type 2 diabetes. Clinical trial phase II results show that there is clinically relevant improvement in symptoms associated with small fiber neuropathy; improved peripheral nerve regeneration; and positive changes in certain metabolic parameters (e.g., HbA1C).

Phase II trials by Dahan et al. demonstrate significant improvement in various neuropathic endpoint measures, combined with improved blood glucose control. These two benefits make ARA-290 a potential compound for future research in areas including the interplay between metabolic disease and neurodegenerative disorders; microvascular health; and overall prevention or treatment of diabetes related complication.

5. Robust Cardiac, Renal, and Organ Protection Against Ischemia-Reperfusion Injury
Ara-290 has been shown to provide strong protective functions against ischemic/reperfusion (IRR) induced damage in all vital organs by greatly reducing damage due to the stress of ischemia/IR. By utilizing the protective mechanisms that are IRR-induced through both anti-apoptotic and anti-inflammatory pathways, Ara-290 decreases infarct sizes in heart models, preserves renal function, and limits the amount of injury to multiple organs during intense metabolic or hypoxemic stresses.

The pre-clinical evidence shows that Ara-290 can serve as a “chemical shield” to protect cells and maintain organ function under extreme conditions; thus, it is an attractive compound for the study of cardiovascular health, kidney disease, and protecting tissues during perioperative and critical care situations.

Why Choose Our ARA-290 Injector Pen in the UAE?

ARA-290 is produced under strict clinical-grade conditions using high-quality processes. ARA-290 undergoes rigorous third party testing to ensure it is stable, pure and potent. ARA-290 can be administered through an easy-to-use, pre-filled syringe eliminating all of the preparatory steps that make administering other products so time-consuming and complicated. It also provides a consistent dose every single time you administer it, providing predictable results when utilizing ARA-290 in your advanced tissue repair studies; neuropathy; metabolic studies; organ protective studies; and/or as part of your search for new ways to heal.

ARA-290 has been used as a treatment option in multiple human clinical trials to treat neuropathic pain; regenerate nerves; improve metabolic function; protect organs from damage; and support innovative therapeutic applications. Because ARA-290 is a product that may be utilized in clinical settings, always seek input from a qualified healthcare professional or research ethics committee prior to implementing any study protocol. These statements are solely educational in nature and represent the compilation of information contained within published scientific literature. Statements provided do not provide medical advice nor does it intend to promote the diagnosis, treatment, prevention or cure of any diseases.

Important Note: This product is intended strictly for research and laboratory use only. It is not for personal consumption, human or animal therapeutic use, or any clinical application. Please consult and comply with all local regulations in the UAE before purchasing or handling.